UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) – September 27, 2019
|
|
| WEST PHARMACEUTICAL SERVICES, INC. |
(Exact name of registrant as specified in its charter)
|
| | | | | | |
| | | | | | | |
| Pennsylvania | | 1-8036 | | 23-1210010 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | | | | | | |
| 530 Herman O. West Drive, | Exton, | PA | | | | 19341-0645 |
| (Address of principal executive offices) | | | | (Zip Code) |
Registrant’s telephone number, including area code: 610-594-2900
|
|
| Not Applicable |
| (Former name or address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
| |
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
| |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
| |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
| |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: |
| | |
| Title of each class | Trading Symbol | Name of each exchange on which registered |
| Common Stock, par value $0.25 per share | WST | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 27, 2019, West Pharmaceutical Services (the “Company”) appointed Senior Vice President, Chief Financial Officer and Treasurer, Bernard J. Birkett, to the role of Principal Accounting Officer, effective as of October 7, 2019, following the decision of Daniel Malone, Vice President and Corporate Controller, to retire on December 31, 2019. Mr. Birkett’s appointment will be in addition to his current duties. Mr. Malone’s departure is not related to any disagreement with the Company’s accounting, operating policies or practices.
No new compensatory arrangements will be entered into with Mr. Birkett in connection with his appointment as the Company’s Principal Accounting Officer. Mr. Birkett was not appointed as the Company’s Principal Accounting Officer pursuant to any arrangement or understanding with any other person. Mr. Birkett does not have any family relationships with any executive officer or director of the Company, and he is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| |
| | WEST PHARMACEUTICAL SERVICES, INC. |
| | |
| | |
| | /s/ George L. Miller |
| | George L. Miller |
| | Senior Vice President, General Counsel and Corporate Secretary |
| | |
| | |
| October 2, 2019 | |
